123 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
21 Available Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Condition: Advanced Breast Cancer (Female)
Interventions: Drug: Palbociclib;   Drug: Letrozole
22 Available International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Conditions: Metastatic Gastric Cancer;   Metastatic Adenocarcinoma of the Gastroesophageal Junction
Intervention: Biological: Ramucirumab
23 Available EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
24 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Conditions: GBM;   Glioblastoma Multiforme
Intervention: Biological: DCVax-L
25 Available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Conditions: Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Biological: G-CSF mobilized CD34+ selected cells for transplantation
26 Available Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C
Interventions: Drug: Telaprevir + peginterferon alfa + ribavirin;   Drug: peginterferon alfa + ribavirin
27 Available Ruxolitinib for Chuvash Polycythemia
Condition: Chuvash Polycythemia
Intervention: Drug: Ruxolitinib
28 Available Cartilage Tissue Engineering
Condition: Mesenchymal Stem Cells
Intervention: Other: total knee / hip replacement
29 Available Emergency/Compassionate Use PFO Occluder
Conditions: Patent;   Foramen;   Ovale;   PFO
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
30 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
31 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
32 Available Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: nintedanib
33 Available Islet Transplant for Type 1 or Surgical Diabetes
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia;   Labile Diabetes;   End-stage Renal Disease
Intervention: Biological: Allogeneic islets of Langerhans
34 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
35 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE
36 Unknown  Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
37 Available Dextromethorphan Added on for the Patients With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Dextromethorphan
38 Available Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
Conditions: Graft vs Host Disease;   Graft-Versus-Host Disease
Intervention: Biological: remestemcel-L
39 Available Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)
Condition: Stage III (Unresectable) or Stage IV Advanced Melanoma
Intervention: Drug: Nivolumab
40 Unknown  Second Line Therapy to Treat Age-Related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Condition: Age Related Macular Degeneration
Interventions: Drug: Visudyne;   Drug: Lucentis;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years